Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy - PubMed (original) (raw)
Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy
Peter M Rothwell et al. Lancet. 2005 Jan.
Abstract
Clinicians often have to make treatment decisions based on the likelihood that an individual patient will benefit. In this article we consider the relevance of relative and absolute risk reductions, and draw attention to the importance of expressing the results of trials and subgroup analyses in terms of absolute risk. We describe the limitations of univariate subgroup analysis in situations in which there are several determinants of treatment effect, and review the potential for targeting treatments with risk models, especially when benefit is probably going to be dependent on the absolute risk of adverse outcomes with or without treatment. The ability to systematically take into account the characteristics of an individual patient and their interactions, to consider the risks and benefits of interventions separately if needed, and to provide patients with personalised estimates of their likelihood of benefit is shown using the example of endarterectomy for symptomatic carotid stenosis.
Similar articles
- Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Chaturvedi S, Bruno A, Feasby T, Holloway R, Benavente O, Cohen SN, Cote R, Hess D, Saver J, Spence JD, Stern B, Wilterdink J; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Chaturvedi S, et al. Neurology. 2005 Sep 27;65(6):794-801. doi: 10.1212/01.wnl.0000176036.07558.82. Neurology. 2005. PMID: 16186516 Review. - Carotid endarterectomy: is it still a gold standard?
Rubio F, Martínez-Yélamos S, Cardona P, Krupinski J. Rubio F, et al. Cerebrovasc Dis. 2005;20 Suppl 2:119-22. doi: 10.1159/000089364. Epub 2005 Dec 2. Cerebrovasc Dis. 2005. PMID: 16327261 Review. - Endovascular stenting or carotid endarterectomy for treatment of carotid stenosis: a meta-analysis.
Guay J. Guay J. J Cardiothorac Vasc Anesth. 2011 Dec;25(6):1024-9. doi: 10.1053/j.jvca.2011.01.009. Epub 2011 Mar 12. J Cardiothorac Vasc Anesth. 2011. PMID: 21398144 Review. - A review of the trials comparing carotid endarterectomy and carotid angioplasty and stenting.
Ricotta JJ 2nd, Malgor RD. Ricotta JJ 2nd, et al. Perspect Vasc Surg Endovasc Ther. 2008 Sep;20(3):299-308. doi: 10.1177/1531003508324614. Epub 2008 Sep 25. Perspect Vasc Surg Endovasc Ther. 2008. PMID: 18818232 Review.
Cited by
- The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.
Kent DM, van Klaveren D, Paulus JK, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. Kent DM, et al. Ann Intern Med. 2020 Jan 7;172(1):W1-W25. doi: 10.7326/M18-3668. Epub 2019 Nov 12. Ann Intern Med. 2020. PMID: 31711094 Free PMC article. - Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Kataoka H, Mochizuki T, Ohara M, Tsuruta Y, Iwasa N, Yoshida R, Tsuchiya K, Nitta K, Kimura K, Hosoya T; FEATHER Investigators. Kataoka H, et al. Sci Rep. 2022 Mar 8;12(1):3784. doi: 10.1038/s41598-022-07737-9. Sci Rep. 2022. PMID: 35260678 Free PMC article. Clinical Trial. - Impact of the PATH Statement on Analysis and Reporting of Heterogeneity of Treatment Effect in Clinical Trials: A Scoping Review.
Selby JV, Maas CCHM, Fireman BH, Kent DM. Selby JV, et al. medRxiv [Preprint]. 2024 May 6:2024.05.06.24306774. doi: 10.1101/2024.05.06.24306774. medRxiv. 2024. PMID: 38766150 Free PMC article. Preprint. - A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies.
Li J, Zhao L, Tian L, Cai T, Claggett B, Callegaro A, Dizier B, Spiessens B, Ulloa-Montoya F, Wei LJ. Li J, et al. Biometrics. 2016 Sep;72(3):877-87. doi: 10.1111/biom.12461. Epub 2015 Dec 21. Biometrics. 2016. PMID: 26689167 Free PMC article. - Competing risk and heterogeneity of treatment effect in clinical trials.
Kent DM, Alsheikh-Ali A, Hayward RA. Kent DM, et al. Trials. 2008 May 22;9:30. doi: 10.1186/1745-6215-9-30. Trials. 2008. PMID: 18498644 Free PMC article.